MPS

Download Flyer

Cardiovascular & Hematological Disorders-Drug Targets

ISSN: 1871-529X (Print)
eISSN: 2212-4063 (Online)

Scopus
CiteScore:

1.9

Aims and Scope:Cardiovascular & Hematological Disorders-Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of in-depth/mini reviews, original research articles, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

Editor-in-Chief:

Pietro Scicchitano Department of Cardiology
Hospital "F. Perinei"
Bari
Italy

Indexed in:

Scopus, MEDLINE/PubMed, Cabell's Directory/Journalytics... View all

Special Issues With Active Call for Papers

Submission closes on: May 21, 2026

Innovative Approaches for Monitoring Cardiological and Hematological Patients

In recent years, the scientific community has become particularly interested in the frontier areas of medical science: telemedicine, big data, artificial intelligence, and biomarkers. At the same time, an interdisciplinary approach in cardiology and hematology is of great importance, given the increasing importance of multimorbidity with the advent of new therapeutic methods for chronic non-communicable diseases. The purpose of this issue was the authors' attempt to reveal the importance of an interdisciplinary approach in cardiology... see more

Guest Editor(s): Andrey Garanin
Co-Guest Editor(s): Dr. Anna Kontsevaya,Dr. Andrey Polupanov,Dr. Olga Tereshina

Start Submission

Submission closes on: Jul 01, 2025

Effective Lowering pf Lipoprotein (a) – A new Frontier in Cardiovascular Risk Reduction

Elevated lipoprotein(a) (Lp[a]) is a genetically determined cardiovascular risk factor, causally linked to both atherosclerotic coronary artery disease and aortic valve stenosis. Elevated Lp(a) is widely prevalent, and several cardiovascular societies now recommend performing Lp(a) screening at least once in all adults. While, there are currently no approved drugs aimed specifically at lowering Lp(a), there are several promising Lp(a)-lowering therapies in the drug development pipeline and likely to get approved in the coming months. We... see more

Guest Editor(s): Mukherjee Debabrata
Co-Guest Editor(s): Dr. Richard Lange